{
    "2019-08-25": [
        [
            {
                "time": "",
                "original_text": "【川财研究所*业绩点评】泰格医药（300347）：咨询业务毛利率大幅提升，期间费用率持续改善",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "咨询业务",
                        "毛利率",
                        "大幅提升",
                        "期间费用率",
                        "持续改善"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}